

Company name----- * Website----- Leal Health www.leal.health----- *

CEO name-----* Cell phone number & Email-----Tzvia

Select a CATEGORY: Health IT/Digital *

Select one SESSION per abstract from the list below *

)

Reinventing Clinical Trials: New Models, Technologies, and Companies .1

Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. ●

Leal Health is the leading Patient-first, AI-powered treatment decision support platform dedicated to improving cancer treatment access, matching patients to all available options—approved therapies and clinical trials—in minutes, not months. The platform’s mission is to democratize access to cancer treatments for all patients. Key achievements include supporting over 300,000 cancer patients, 35% of whom are minority patients, with 70% served in the community setting, and an engaged community of over 24,000 HCPs and oncologists. The company works with more than 80 biopharma partners and leverages patented AI technology through tools like Leal’s Patient Clinical Trial Prescreener & Match Platform and Leal’s Biomarker(NGS) Report Analyzer to support every key stakeholder in the patient journey. Leal Health has been recognized by **TIME** as one of the 100 Most Innovative Companies and partners with industry leaders such as Tempus, American Cancer Society, and Evernorth- Cigna Health

Core Technology: What is the technology, its uniqueness, and its value proposition? ●

At the heart of Leal Health is our innovative patented Precision Medical Modeling (“PMM”) technology, which leverages machine learning algorithms, LLMs, and unsupervised natural language processing to analyze vast datasets from patient records, including NGS testing, clinical trial protocols, and advanced medical literature.

This AI-driven approach accelerates the identification of suitable clinical trials and treatment options tailored to each patient's unique profile. By automating the matching process, our technology significantly reduces the time and effort required to enroll patients in trials and ensures that more diverse and qualified participants are recruited.

Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. ●

Leal's approach is distinguished by a profound understanding of patients' journeys. We use powerful AI-based tools to empower and support patients while building a comprehensive 147-data point picture of each patient, mapping their full medical profile, including genetic mapping, individual drivers and barriers. Leal's approach to patient centricity draws on hundreds of thousands of individual patient experiences. We have built our technological solutions around the needs patients experience throughout their journey, addressing factors that may impede or drive patients to make treatment decisions, including joining a clinical trial. From financial toxicity constraints to study design concerns, Leal's multiple AI-based solutions remove some of the main barriers patients face while searching for their treatment options and highlighting for sponsors where the gaps and opportunities lie.

Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. ●

Since 2020, we have engaged and partnered with over 80 pharma companies (including We provided the both big pharma and SMBs), CROs, and other health organizations. industry with services related to clinical matching, prequalification, education and engagement of patients for and in treatment. While extracting over 147 unique data points on the patients medical info, PRO and journey barriers and, enabling the industry to optimize the clinical trial design & operation. Leal maintains ongoing partnerships with dozens of cancer patient organizations that use our platform to successfully match their community members to clinical trials and other treatment options

What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans ●

Leal is planning to expand to new geographical territories like EU and Asia, while expanding to additional medical conditions such as rare diseases